ClinicalTrials.gg
Active, not recruitingNCT06150183Updated Sep 15, 2026

Safety and Preliminary Efficacy of BNT314 in Cancer Patients With Malignant Solid Tumors

A Phase 1 interventional study of BNT314 in Advanced Malignant Solid Tumor, sponsored by BioNTech SE. Active, not recruiting at 14 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-15.

Sponsored by BioNTech SE · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
41
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this first-in-human study is to find out if BNT314 is safe when it is used alone in patients with different types of cancer.

This is a dose escalation study in which patients will be assigned to multiple dose levels (DLs) of BNT314 given alone. By escalating the dose with a small group of patients, the Maximum Tolerated Dose which is the highest dose with acceptable safety and manageable side effects, or the maximum administered dose will be investigated.

Read the detailed description

This is a multicenter, multinational safety study in patients with metastatic or advanced malignant solid tumors for whom, at the discretion of the investigator, there is no available standard therapy likely to confer clinical benefit, evaluating the safety, tolerability, preliminary antitumor activity, pharmacokinetics (PK), pharmacodynamics, and immunogenicity of BNT314.

During dose escalation, BNT314 will be administered to patients via one infusion in periodic cycles.

Additional cohorts (backfill cohorts) administering BNT314 as monotherapy will assign patients to specific DLs, based on the emerging safety, PK, and pharmacodynamic data. This would allow for further assessment of dose- and exposure-response relationships for clinical activity, safety, and tolerability to support BNT314 dose optimization.

The treatment period will last until progressive disease (PD), confirmed PD (as per immune Response Evaluation Criteria in Solid Tumors [iRECIST]), unacceptable toxicity, or withdrawal of consent, whichever happens first.

The maximum duration of BNT314 administration in this study is 2 years.

02

Conditions studied

  • Advanced Malignant Solid Tumor

Keywords

  • Malignant solid tumors
03

In context

Lead sponsor

BioNTech SE is the lead sponsor of 76 studies on the registry; 24 are open to participants now.

Of its 33 completed or terminated interventional studies of FDA-regulated products, 26 (79%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Have the ability to voluntarily give by signing and dating the informed consent form (ICF) before initiation of any study-specific procedures.
  2. Are willing and able to comply with scheduled visits, treatment schedule, laboratory tests, lifestyle restrictions, and other requirements of the study. This includes that they are able to understand and follow study-related instructions.
  3. Are ≥18 years of age at the time of giving informed consent.
  4. Have according to v1.1.
  5. Have a of >3 months.
  6. Have Performance Status score of 0 or 1 at screening.
  7. Have adequate coagulation function at screening as determined by:

    • or prothrombin time ≤1.5 × upper limit normal (; unless on therapeutic anticoagulants with values within therapeutic window).
    • Activated partial thromboplastin time ≤1.5 × ULN (unless on therapeutic anticoagulants with values within therapeutic window).
  8. Have adequate bone marrow/hematologic function at screening as determined by:

    • (ANC) ≥1.5 × 10\^9/L (≥1500/μL) (patients may not use granulocyte colony stimulating factor or granulocyte-macrophage colony stimulating factor to achieve these ANC levels in the past 7 days).
    • count ≥100 × 10\^9/L (≥100,000/μL).
    • ≥9 g/dL.
    • Any blood transfusions ≤28 days before first dose of study treatment should be documented.
  9. Have adequate hepatic function at screening as determined by:

    • Total (Tbili) ≤1.5 × ULN OR direct bilirubin ≤ULN for patients with Tbili levels >1.5 × ULN. Patients with Gilbert's syndrome must have a Tbili \<3 mg/dL and direct bilirubin ≤ULN.
    • and aspartate aminotransferase ≤2.5 ULN for patients with or without liver .
    • Albumin ≥30 g/L.
  10. Have adequate renal function at screening as determined by ≥45 mL/min/1.73 m\^2 according to the abbreviated Modification of Diet in Renal Disease equation.
  11. Have adequate pancreas function at screening as determined by amylase and lipase with no signs and symptoms of pancreatitis.
  12. Patients of (POCBP) must have a negative urine or blood beta human chorionic gonadotropin test at screening. Patients that are or permanently sterilized (verified by medical records) will not be considered POCBP, and therefore are not required to undergo pregnancy testing.
  13. POCBP must agree to practice a highly effective form of and to require their male partners to use condoms coated with a spermicidal agent, starting at Visit D1 and thereafter until 120 days after receiving the last study treatment.
  14. POCBP must agree not to donate eggs (ova, oocytes) for the purposes of assisted reproduction during study, starting at Visit D1 and thereafter until 120 days after receiving the last study treatment.
  15. Males who are sexually active and have not had a bilateral vasectomy or orchidectomy must agree to use condoms coated with a spermicidal agent and to require their female partners to practice a highly effective form of contraception during the study, starting at Visit D1 and thereafter until 120 days after receiving the last study treatment.
  16. Males must be willing to refrain from sperm donation, starting at Visit D1 and thereafter until 120 days (one sperm cycle) after receiving the last study treatment.
  17. Patients must have a confirmed advanced malignant solid tumor, having experienced disease progression on or after standard therapy, or were intolerant of or not eligible for standard therapy.

Other inclusion criteria specific to selected tumor indications may apply.

Exclusion criteria

Exclusion Criteria:

  1. Patients that have uncontrolled intercurrent illness, including but not limited to:

    • Ongoing or active infection requiring treatment with anti-infective therapy administered less than 2 weeks prior to first dose.
    • Symptomatic congestive heart failure (Grade III or IV as classified by the ), unstable angina pectoris, or symptomatic untreated cardiac arrhythmia. Treated and/or asymptomatic cardiac arrythmia/atrial fibrillation will be allowed.
    • History of arterial thrombosis or pulmonary embolism within 6 months before the first dose of study treatment.
    • History of myocardial infarction within 6 months before the first dose of study treatment.
    • Uncontrolled hypertension defined as systolic blood pressure ≥160 mm Hg and/or diastolic blood pressure ≥100 mm Hg, despite optimal medical management.
    • Prolonged at baseline of ≥470 milliseconds using Fridericia's QT correction formula.
    • Ongoing or recent (within one year of screening) evidence of significant disease that required treatment with systemic treatments, which may suggest risk for immune-related adverse events.
    • History of:

      • Grade 2 immune-mediated myocarditis/colitis/pneumonitis that led to (CPI) discontinuation. Patients experiencing other Grade 2 immune-mediated adverse events that led to CPI discontinuation, require discussion with the sponsor.
      • Any Grade ≥3 immune-mediated adverse events that led to CPI discontinuation.
      • Patients with Grade 3 adverse events that led to CPI discontinuation but resolved within 21 days without sequalae may also be considered for discussion with the sponsor.
    • History of chronic liver disease (e.g., alcoholic hepatitis or nonalcoholic steatohepatitis, drug-related or autoimmune hepatitis) or evidence of hepatic cirrhosis.
    • History of non-treated intracerebral arteriovenous malformation (shunts), non-treated cerebral aneurysm, spinal cord compression (from disease), carcinomatous meningitis, or stroke will be excluded.
    • History of acute or chronic pancreatitis of any etiology within 6 weeks prior to the start of study treatment.
    • Ongoing pneumonitis or history of noninfectious pneumonitis that has required or evidence of interstitial lung disease.
    • less than one month prior to screening will be excluded.
    • History of brain/central nervous system (CNS) . Patients with newly identified or known unstable or symptomatic will be excluded. Patients with previously treated brain metastases are allowed provided lesions are radiologically stable (i.e., without evidence of progression) for at least 28 days by repeat imaging, latest imaging performed maximum 6 weeks prior to Cycle 1, Day 1.
    • Serious, non-healing wound, skin ulcer (of any grade), or bone fracture will be excluded.
    • Other concurrent severe and/or uncontrolled medical condition that would, in the investigator's judgment, contraindicate patient participation in this clinical study (e.g., acute or chronic pancreatitis, active hepatitis). Known primary immunodeficiencies, either cellular (e.g., DiGeorge syndrome, T-cell negative severe combined immunodeficiency [SCID] or combined T- and B-cell immunodeficiencies (e.g., T- and B-cell negative SCID, Wiskott Aldrich syndrome, ataxia telangiectasia, common variable immunodeficiency).
    • Major surgery within 3 weeks before signature of the ICF unless fully recovered from the surgery in the opinion of the investigator.
    • Any positive test for (defined as positive for hepatitis B surface antigen or hepatitis B virus DNA), indicating acute or chronic infection.
    • Any positive test for (defined as positive for hepatitis C virus antibody or hepatitis C virus RNA), indicating acute or chronic infection.
  2. Prior therapy:

    • Radiotherapy within 14 days prior to first BNT314 administration. Palliative radiotherapy will be allowed, but not to target lesions.
    • Any epithelial cell adhesion molecule- or 4-1BB-targeting treatment.
    • Treatment with an anticancer agent within 4 weeks or for systemic therapies after at least five half-lives of the drug, whichever is shorter, prior to study treatment administration.
    • Patient has received any agent (including investigational vaccines) or used an invasive investigational medical device within 28 days before the planned first dose of BNT314 or is currently enrolled in an (another) interventional study. Patients who are in the follow-up phase of an interventional study may participate if they have not received an investigational agent within 28 days (or five half-lives, whichever is longer) of the first dose of BNT314.
    • Patient has a condition requiring systemic treatment with either corticosteroids (>10 mg daily prednisone or equivalent) or other immunosuppressive medications within 14 days of the first dose of BNT314. Inhaled or topical steroids, and adrenal or pituitary replacement steroid >10 mg daily prednisone or equivalent, are permitted in the absence of active autoimmune disease.
    • Patient has received granulocyte or granulocyte/macrophage colony stimulating factor (G-CSF/GM-CSF) support within 4 weeks prior to first BNT314 administration or is chronically transfusion dependent; G-CSF and other hematopoietic factors may be used in the management of acute toxicity (such as febrile neutropenia) or prophylactically, when clinically indicated at the investigator's discretion.
    • Received any within 30 days prior to the start of study treatment.
  3. Known alcohol dependency within 6 months enrollment in this study.
  4. Planned enrollment in another study of an IMP, starting after Visit D1 and continuously until the last planned visit in this study.
  5. Have a medical, psychological, or social condition which, in the opinion of the investigator, could compromise their wellbeing if they participate in the study, or that could prevent, limit, or confound the protocol specified assessments or procedures, or that could impact adherence to protocol-described requirements.
  6. Are subject to exclusion periods from another investigational study.
  7. Are vulnerable individuals as per International Council for Harmonisation E6 definition, i.e., are individuals whose willingness to participate in a clinical study may be unduly influenced by the expectation, whether justified or not, of benefits associated with participation, or of a retaliatory response from senior members of a hierarchy in case of refusal to participate.
  8. Has (known allergies, , or intolerance) to the use of BNT314. A patient with a history of hypersensitivity to any component/ of BNT314 is also excluded.
  9. Are pregnant or breastfeeding and cannot discontinue breastfeeding for the duration of the study and for 4 months after receiving the last dose of BNT314.
Terms in these criteria, in plain language(33)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
41 participants (actual)

Study arms

  • Experimental
    BNT314 Monotherapy

    Escalating dose levels and backfill cohorts

    Biological: BNT314

Interventions

  • BiologicalBNT314

    Intravenous infusion

06

What researchers measure

Primary outcomes

  1. Occurrence of dose-limiting toxicity within a cohort

    Time frame: 21 days from the first dose administration

  2. Number and percentage of patients with occurrence of treatment-emergent adverse events (TEAEs) including Grade ≥ 3, serious, fatal TEAE by relationship

    In patients receiving at least one dose of BNT314 per cohort

    Time frame: from first dose of study treatment to 90 days after last dose of study treatment

  3. Number and percentage of patients with occurrence of dose reduction and discontinuation of investigational medicinal product (IMP) due to TEAE

    In patients receiving at least one dose of BNT314 per cohort

    Time frame: from first dose of study treatment to 90 days after last dose of study treatment

  4. Number and percentage of patients with occurrence of Grade ≥ 3 abnormal safety laboratory parameters

    In patients receiving at least one dose of BNT314 per cohort

    Time frame: from first dose of study treatment to 90 days after last dose of study treatment

Secondary outcomes

  1. Geometric means of area under the concentration-time curve from pre-dose to last quantifiable time point prior to the next dose (AUClast)

    In patients receiving at least one dose of BNT314 per cohort and are evaluable for PK assessments

    Time frame: from pre-dose to 21 days after study treatment for Cycle 1 and Cycle 2

  2. Geometric means of area under the concentration-time curve from pre-dose to the end of the dosing period (AUCtau)

    In patients receiving at least one dose of BNT314 per cohort and are evaluable for PK assessments

    Time frame: from pre-dose to 21 days after study treatment for Cycle 1 and Cycle 2

  3. Geometric means of maximum concentration (Cmax) from pre-dose to the end of the dosing period

    In patients receiving at least one dose of BNT314 per cohort and are evaluable for PK assessments

    Time frame: from pre-dose to 21 days after study treatment for Cycle 1 and Cycle 2

  4. Number and percentage of patients who developed detectable anti-drug antibody from baseline to the end of study treatment

    In patients receiving at least one dose of BNT314 per cohort

    Time frame: from pre-dose to 90 days after last dose of study treatment

  5. Disease control rate based on investigator's tumor assessment according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)

    Reported with number and percentage of patients with a confirmed complete response (CR), partial response (PR), or stable disease (SD) (assessed at least 6 weeks after first dose of study treatment) as best overall response. In patients receiving at least one dose of BNT314

    Time frame: up to 3 years after first dose of study treatment

  6. Objective response rate based on investigator's tumor assessment according to RECIST v1.1

    Reported with number and percentage of patients with a confirmed CR or PR as best overall response. In patients receiving at least one dose of BNT314.

    Time frame: up to 3 years after first dose of study treatment

  7. Duration of response (DOR) based on investigator's tumor assessment according to RECIST v1.1

    DOR is defined as the time from first objective response (CR or PR) to first occurrence of objective tumor progression or death from any cause, whichever occurs first. In patients receiving at least one dose of BNT314.

    Time frame: up to 3 years after first dose of study treatment

07

Study locations

14 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2023 to primary completion in Aug 2026, 32 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 21, 2023
First posted
Nov 29, 2023
StartActual
Nov 30, 2023
Primary completionActual
Aug 18, 2026
CompletionEst.
Nov 2026
Last update
Sep 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06150183
Lead sponsor
BioNTech SE
Collaborators
Genmab
Responsible party
Sponsor
First posted
Nov 29, 2023
Start date
Nov 30, 2023
Primary completion
Aug 18, 2026
Completion
Nov 2026 (estimated)
Last update
Sep 15, 2026

Study contacts

BioNTech Responsible Person
study director · BioNTech SE

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion